Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
University of Florida
Endeavor Biomedicines, Inc.
Emory University
Eli Lilly and Company
Milton S. Hershey Medical Center
Children's Oncology Group
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
USWM, LLC (dba US WorldMeds)
St. Jude Children's Research Hospital
Baylor College of Medicine
National Cancer Institute (NCI)
Children's National Research Institute
Baylor College of Medicine
GlaxoSmithKline
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Emory University
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
University of Wisconsin, Madison
Novartis
Hadassah Medical Organization
Valent Technologies, LLC
UNC Lineberger Comprehensive Cancer Center
Nationwide Children's Hospital
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
Children's Hospital of Philadelphia
City of Hope Medical Center
Medical College of Wisconsin
Meyer Children's Hospital IRCCS
Bambino Gesù Hospital and Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)